Related Experiment Videos
CD154 blockade results in transient reduction in Theiler's murine encephalomyelitis virus-induced demyelinating
Laurence M Howard1, Katherine L Neville, Lia M Haynes
1Departments of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA.
Abstract:
Transient CD154 blockade at the onset of Theiler's murine encephalomyelitis virus-induced demyelinating disease ameliorated disease progression for 80 days, reduced immune cell infiltration, and transiently increased viral loads in the central nervous system. Peripheral antiviral and autoimmune T-cell responses were normal, and disease severity returned to control levels by day 120.
Insights
Transient CD154 blockade temporarily eased Theiler's murine encephalomyelitis virus-induced demyelinating disease, reducing immune cell infiltration. However, viral loads increased, and disease severity eventually returned to normal levels.
Area of Science:
- Neuroimmunology
- Virology
- Immunotherapy
Background:
- Theiler's murine encephalomyelitis virus (TMEV) infection causes demyelinating disease in mice, serving as a model for multiple sclerosis.
- CD154 (CD40 ligand) plays a critical role in T-cell activation and immune responses, potentially influencing viral-induced demyelination.
Purpose of the Study:
- To investigate the therapeutic potential of transient CD154 blockade in the early stages of TMEV-induced demyelinating disease.
- To assess the impact of CD154 blockade on viral load, immune cell infiltration, and disease progression in the central nervous system.
Main Methods:
- Mice were infected with TMEV, and transient CD154 blockade was administered at the onset of demyelinating disease.
- Disease severity, viral loads in the central nervous system, and immune cell infiltration were monitored over time.
- Peripheral T-cell responses were analyzed to evaluate systemic immune modulation.
Main Results:
- Transient CD154 blockade significantly ameliorated disease progression for up to 80 days post-infection.
- A temporary increase in viral loads within the central nervous system was observed following CD154 blockade.
- Reduced immune cell infiltration into the central nervous system was noted, but peripheral antiviral and autoimmune T-cell responses remained largely unaffected.
Conclusions:
- Early transient CD154 blockade offers a temporary therapeutic benefit in TMEV-induced demyelinating disease by modulating neuroinflammation.
- The observed transient increase in viral load warrants further investigation into the complex interplay between CD154, viral replication, and immune control.
- Long-term efficacy is limited, as disease severity returned to control levels by day 120, suggesting the need for alternative or combination therapeutic strategies.